The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 trial of durvalumab plus intravesical gemcitabine and docetaxel in BCG-unresponsive non-muscle invasive bladder cancer patients (HCRN GU16-243: ADAPT-BLADDER Cohort 4).
 
Noah Hahn
Consulting or Advisory Role - AstraZeneca; BioGears; EMD Serono; Guidepoint Pharmacy; Huron Consulting; Incyte; Janssen; Merck; Mirati Therapeutics; Natera; Pfizer; Protara Therapeutics; Seattle Genetics/Astellas; Tyra Biosciences; Verity Pharmaceuticals
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); HTG Molecular Diagnostics (Inst); Ikena Oncology (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); Loxo (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Seattle Genetics/Astellas (Inst)
Patents, Royalties, Other Intellectual Property - Provisional US patent for an immune-based biomarker to predict response to immunotherapy in patients with advanced bladder cancer
 
Marianna Zahurak
No Relationships to Disclose
 
Hristos Kaimakliotis
No Relationships to Disclose
 
Timothy Masterson
No Relationships to Disclose
 
Nabil Adra
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol Myers Squibb Foundation; Bristol Myers Squibb Foundation; EMD Serono; Exelixis; Merck; Sanofi
Research Funding - Exelixis (Inst); Genentech (Inst); Merck (Inst); Natera (Inst)
 
David Chen
Stock and Other Ownership Interests - Pfizer; Pfizer (I)
 
Alexander Kutikov
Travel, Accommodations, Expenses - Pfizer
 
Daniel Geynisman
Honoraria - Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Exelixis; Merck; Pfizer; Seattle Genetics/Astellas
Research Funding - Arvinas (Inst); Astellas Pharma (Inst); CG Oncology (Inst); Harpoon therapeutics (Inst); Merck (Inst)
 
Woodson Smelser
No Relationships to Disclose
 
Melissa Reimers
Honoraria - Society of Urologic Nurses and Associates (SUNA)
Consulting or Advisory Role - Astellas Pharma; Loxo; Pathos AI, Inc
Research Funding - Amgen (Inst); AstraZeneca (Inst); BMS GmbH & Co. KG (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); Genentech (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); ProfoundBio (Inst)
 
Christopher Anderson
No Relationships to Disclose
 
Mark Stein
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Exelixis; Exelixis; Janssen Oncology; Merck Sharp & Dohme; Vaccitech; Xencor
Research Funding - Advaxis (Inst); AstraZeneca (Inst); Bellicum Pharmaceuticals; Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Janssen Oncology (Inst); Lilly (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Oncoceutics (Inst); Regeneron (Inst); Seagen (Inst); Suzhou Kintor Pharmaceuticals (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst)
 
Alexander Baras
No Relationships to Disclose
 
Gabriela Colocho
No Relationships to Disclose
 
Deborah Schwartz
No Relationships to Disclose
 
David McConkey
Honoraria - H3 Biomedicine; Janssen Oncology
Consulting or Advisory Role - CG Oncology
Research Funding - Convergent Genomics
 
Sunil Patel
No Relationships to Disclose
 
Bilal Rahim
No Relationships to Disclose
 
Michael O'Donnell
Consulting or Advisory Role - Fidia Pharma USA; Merck; Photocure; Theralase; UroGen pharma; Vaxiion Therapeutics
 
Max Kates
Consulting or Advisory Role - FerGene; Genesis Biotechnology Group; Janssen; Pacific Edge